# Ipamorelin Research: Mechanism, Studies, and the Newest Findings > Ipamorelin research by tissue and study: GHS-R1a selectivity, human PK, the failed Phase 2 ileus trial, rat bone growth, the 2024 ferret cachexia result, and 2026 reviews — all cited. Mechanism, the human pharmacokinetics, the one failed human trial, and the freshest 2024–2026 work, each carried back to its source. ## The short version Ipamorelin research is wide on mechanism and narrow on human outcomes. The founding study showed it releases growth hormone cleanly — strong pulse, little cortisol or prolactin [1]. A human pharmacology study pinned its half-life near two hours [2]. The one mid-stage human trial, for slow bowel recovery after surgery, did not beat placebo [3]. Animal work fills in the rest: dose-dependent bone growth in rats [4], a 2024 ferret study where it cut chemotherapy weight loss by about a quarter [5], and a direct effect on the pancreas [11]. The newest 2026 reviews call it promising in animals and unproven in people [14][15][16][17]. This page walks each of those, newest first. ## The newest data: a 2024 cachexia result and 2026 reviews The freshest in-vivo study is from 2024. In a ferret model of cisplatin chemotherapy, intraperitoneal ipamorelin at 1–3 mg/kg inhibited body-weight loss by about 24% on the last day of the delayed phase (48–72 h) — but had no anti-emetic effect on either acute or delayed emesis, in contrast to central anamorelin, which cut acute emesis by 60% [5]. The takeaway is mechanistic: ipamorelin's weight-protective effect here is peripheral, not a nausea fix. The 2026 review wave is unanimous on the evidence ceiling. An orthopaedic narrative review found CJC-1295 plus ipamorelin improved maximum tetanic tension in a glucocorticoid muscle-loss model in mice while flagging that the evidence is animal-only [14]. A sports-medicine review classified ipamorelin as an investigational growth-hormone-axis peptide with no reproducible human musculoskeletal evidence and urged confining use to research protocols [17]. A broader sports-medicine safety-and-efficacy review reached the same place and emphasized the potential for serious harm [15]; a metabolic/endocrine therapeutic-peptide review placed ipamorelin among unapproved compounds needing human study before safe use [16]. ## Mechanism: GHS-R1a selectivity Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a selective agonist of GHS-R1a, the ghrelin receptor, on pituitary somatotrophs (the growth-hormone-secreting cells). Binding triggers a Gq/phospholipase-C cascade, intracellular calcium rises, and growth hormone is released as a discrete pulse [1]. The defining result: in rat pituitary cells, rats, and swine, ipamorelin matched GHRP-6's growth-hormone potency (swine ED50 = 2.3 nmol/kg) yet left ACTH and cortisol at GHRH-equivalent levels even above 200× its growth-hormone ED50 [1]. It releases growth hormone by a route distinct from GHRH, which is the mechanistic basis for combining it with GHRH analogs. Its reach is not limited to the pituitary. Ex-vivo rat pancreatic tissue released insulin directly in response to ipamorelin, an effect blunted by L-type calcium-channel, α2-adrenergic, and cholinergic blockade — a peripheral, growth-hormone-independent action [11]. Glucocorticoids do not shut the pathway down: methylprednisolone (5.0 mg/kg/day for 8 days) did not blunt the acute growth-hormone response in rats, and the combination raised IGF-1 and improved body-weight recovery versus steroid alone [8]. ## What is cjc 1295 ipamorelin What is cjc 1295 ipamorelin: it is a pairing of two different growth-hormone secretagogues, not a single molecule. CJC-1295 is a GHRH analog that works through the GHRH receptor; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist [1]. Because they act through separate receptors, their growth-hormone-releasing effects are mechanistically complementary — the rationale for using them together. A 2026 orthopaedic review reported the pair improved maximum tetanic tension in a glucocorticoid muscle-loss model in mice, while stressing the evidence is animal-only [14]. No human trial has tested the combination for any outcome. ## Ipamorelin cjc-1295 The ipamorelin cjc-1295 combination is the single most-searched ipamorelin topic, and the evidence is entirely preclinical. The case for it is pharmacological: a GHRH analog (CJC-1295) and a ghrelin-receptor agonist (ipamorelin) push growth-hormone release through two different pathways that add together rather than overlap [1]. The strongest recent data point is a 2026 narrative review reporting improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model with the combination [14]. But that is a mouse result inside a review, not a controlled human trial — and the combination has no published human efficacy or safety study of its own. Treating it as established human therapy outruns the data. ## Bone, body composition, and the medicinal-chemistry legacy In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) raised the longitudinal bone-growth rate dose-dependently from 42 µm/day (vehicle) to 44, 50, and 52 µm/day — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The skeletal effect appears partly local and pulse-driven rather than IGF-1-mediated. Large-animal work in swine confirmed the GH-selective profile that distinguishes ipamorelin from earlier GHRPs [10]. Ipamorelin also seeded medicinal chemistry. A peptidomimetic series built on its scaffold reached comparable in-vivo potency (≈2 nmol/kg IV in swine) while achieving roughly 10% oral bioavailability in dogs [9] — showing the pharmacophore could be pushed toward orally active secretagogues, even though ipamorelin itself is not orally bioavailable. The ghrelin system the compound targets is itself implicated in aging muscle: a 2024 study found unacylated ghrelin protected against age-related loss of muscle mass and contractile dysfunction [7] (the tested agent was ghrelin, not ipamorelin). ## Does cjc-1295 ipamorelin work Does cjc-1295 ipamorelin work depends on the standard of proof. In animal models, yes in a narrow sense — a 2026 review reported improved maximum tetanic tension in a murine glucocorticoid muscle-loss model [14], and single-agent rodent studies show real growth-hormone release [1] and bone growth [4]. In controlled human outcome terms, there is no evidence either way: no human trial has tested the combination, and ipamorelin's lone human efficacy trial (for postoperative ileus) missed its primary endpoint [3]. So the combination 'works' as pharmacology and in animals; it is unproven as a human therapy. ## Is ipamorelin fda approved Is ipamorelin fda approved: no. Ipamorelin has never been approved as a drug by the FDA or any other regulatory authority, for any indication [3]. It was investigated for postoperative ileus (NCT00672074), but that Phase 2 trial missed its primary endpoint and no further clinical development followed [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access. It is also prohibited in sport at all times under WADA category S2. Available material is sold strictly as a research chemical. --- A documentation-first desk that reads the newest ipamorelin studies first and carries every figure back to its PubMed source — no clinic behind the name, no medical advice, and nothing dosed, prescribed, or sold.